Roche, Zealand sign deal: What it means for weight loss drug space
In This Article:
Roche (ROG.SW) and Zealand Pharma (ZEAL.CO) stocks are in focus after the company announced an agreement to make amylin, an obesity drug, in a deal valued at $5.3 billion.
Yahoo Finance Senior Health Reporter Anjalee Khemlani joins Market Domination Co-Hosts Julie Hyman and Josh Lipton to examine what the deal means for the pair of pharmaceutical companies and competitors like Eli Lilly (LLY) and Novo Nordisk (NVO).
To watch more expert insights and analysis on the latest market action, check out more Market Domination here.
Related Videos
Terms and Privacy Policy